Caribou Biosciences and DuPont Pioneer Develop New Method to Comprehensively Map the Off-Target Activity of CRISPR-Cas9 Across Entire Genomes



BERKELEY, Calif. & JOHNSTON, Iowa–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, and DuPont Pioneer today announced the Nature Methods publication describing SITE-Seq, a new method for comprehensively mapping CRISPR-Cas9 cleavage sites across the genome of any organism. When compared against other off-target analysis techniques, SITE-Seq detected potential off-target cleavage sites with a higher degree of resolution. This study has significant implications for the commercialization of products developed with CRISPR-Cas9 technology, as robust analytical tools are necessary to ensure the effective use of this gene-editing tool.

The full study, entitled “Mapping the genomic landscape of CRISPR–Cas9 cleavage,” was published today in Nature Methods and details the biochemical method developed by Caribou and DuPont Pioneer scientists to comprehensively map CRISPR-Cas9 cleavage sites within the genome. Importantly, this information can be used to precisely measure the off-target effects of CRISPR-Cas9 genome editing in cell-based applications. Overall, this method will allow researchers to more effectively select CRISPR-Cas9 targets and delivery methods with maximum accuracy and specificity, thereby overcoming some of the concerns associated with potential off-target effects of CRISPR-Cas9.

This new method is expected to have broad applicability as it can be used to comprehensively detect CRISPR-Cas9 cleavage sites across the genome of any organism. The SITE-Seq method, in conjunction with cell-based validation methods, will constitute a robust pipeline for selecting CRISPR-Cas9 reagents for research or product development.

“This research marks a significant step towards the confirmation of CRISPR-Cas9 as a safe and effective gene-editing tool. By providing researchers with a way to accurately map the genomic landscape of CRISPR–Cas9 activity, we can reduce the occurrence of off-target effects by selecting for targets with the highest possible activity and specificity,” said Dr. Rachel Haurwitz, President and CEO of Caribou. “We are delighted at this latest demonstration of the valuable collaboration between Caribou and DuPont Pioneer scientists who are advancing the development of CRISPR-Cas9 applications.”

“The SITE-Seq research is an excellent proof point of productive collaboration between Caribou and DuPont Pioneer for the advancement of CRISPR-Cas technology,” said Dr. Neal Gutterson, vice president, Research & Development at DuPont Pioneer.

About Caribou Biosciences

Caribou is a leading company in CRISPR genome engineering founded by pioneers of CRISPR-Cas9 biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. For more information, including information about obtaining research and commercial licenses, visit and follow the Company @CaribouBio. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc., and “SITE-Seq” is a trademark of Caribou Biosciences, Inc.

DuPont Pioneer is the world’s leading developer and supplier of advanced plant genetics, providing high-quality seeds to farmers in more than 90 countries. Pioneer provides agronomic support and services to help increase farmer productivity and profitability and strives to develop sustainable agricultural systems for people everywhere. Science with Service Delivering Success®

DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs, and thought leaders, we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please visit

Forward-Looking Statements: This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses; and risks related to the agreement entered on December 11, 2015, with The Dow Chemical Company pursuant to which the companies have agreed to effect an all-stock merger of equals, including the completion of the proposed transaction on anticipated terms and timing, the ability to fully and timely realize the expected benefits of the proposed transaction and risks related to the intended business separations contemplated to occur after the completion of the proposed transaction. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

®, ™, SM Trademarks and service marks of DuPont, Pioneer or their respective owners. © 2017 PHII.



Caribou Media Contact:
Feinstein Kean Healthcare
Greg Kelley, 404-836-2302
[email protected]
DuPont Pioneer Media Contact:
Kerrey Kerr-Enskat, 515-423-8251
[email protected]



Business Wire source: